Literature DB >> 16384950

Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania.

Aimee Teo Broman1, Kenny Shum, Beatriz Munoz, Donald D Duncan, Sheila K West.   

Abstract

PURPOSE: To observe the spatial distribution of households with high loads of ocular chlamydia infection in children, before and after mass treatment with azithromycin to determine whether there exists spatial clustering of households with high loads of infection and the spatial scale of the clustering.
METHODS: All residents of a village in Tanzania were invited to participate in the study. A global positioning system unit recorded the location of each house. Mass treatment with azithromycin was offered, with participation above 80%. Active trachoma and swab samples of the conjunctiva were assessed at baseline and at 2, 6, 12, and 18 months after treatment. A k-function analysis was performed to detect clustering of households with high loads of ocular chlamydia in children younger than 8 years.
RESULTS: A total of 1055 villagers were examined during the study; of these, 374 (35.4%) were children younger than 8 years. The total number of households was 215, with 182 (84.6%) households having at least one child. K-function analysis showed clustering of households with high loads of ocular chlamydia at distances up to 2 kilometers (km) at baseline; at 6 months, slight clustering existed within 0.5 km. At 12 and 18 months, high load households clustered at distances up to 1.3 km.
CONCLUSIONS: This analysis suggests that infection spreads between households with children or that nearby households share the same risk factors for infection. Mass treatment has value in lowering infection prevalence within the community, and clustering of households with infection takes up to 1 year to reemerge at the same level as baseline. Re-treatment at yearly intervals may interrupt spread of infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16384950     DOI: 10.1167/iovs.05-0326

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  32 in total

1.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

2.  Community mass treatment with azithromycin for trachoma: Factors associated with change in participation of children from the first to the second round.

Authors:  Elizabeth N Ssemanda; Harran Mkocha; Joshua Levens; Beatriz Munoz; Sheila K West
Journal:  Clin Epidemiol Glob Health       Date:  2015-04

3.  Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.

Authors:  Jithin Yohannan; Bing He; Jiangxia Wang; Gregory Greene; Yvette Schein; Harran Mkocha; Beatriz Munoz; Thomas C Quinn; Charlotte Gaydos; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

Review 4.  Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Authors:  Meraf A Wolle; Sheila K West
Journal:  Expert Rev Anti Infect Ther       Date:  2019-02-18       Impact factor: 5.091

5.  A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.

Authors:  Daniel P Morberg; Wondu Alemayehu; Muluken Melese; Takele Lakew; Alemayehu Sisay; Zhaoxia Zhou; Vicky Cevallos; Catherine E Oldenburg; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  Ophthalmic Epidemiol       Date:  2018-08-28       Impact factor: 1.648

Review 6.  Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis.

Authors:  D Dean
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

7.  Mass treatment with azithromycin for trachoma control: participation clusters in households.

Authors:  Elizabeth N Ssemanda; Beatriz Munoz; Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Robin L Bailey; Ansumana Sillah; Dianne Stare; David C W Mabey; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 8.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

9.  Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine.

Authors:  Laszlo Kari; William M Whitmire; Deborah D Crane; Nathalie Reveneau; John H Carlson; Morgan M Goheen; Ellena M Peterson; Sukumar Pal; Luis M de la Maza; Harlan D Caldwell
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.

Authors:  Jithin Yohannan; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Robin Bailey; Thomas A Lietman; Thomas Quinn; Sheila K West
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.